The SSRI vs SNRI question is one of the most common pharmacology debates in psychiatry — at the prescribing desk and in MRCPsych, RANZCP and USMLE exams alike. Both are first-line antidepressant classes, both act primarily on serotonin, and trial-level efficacy is broadly similar. Yet the difference between blocking one transporter and blocking two changes the side-effect profile, the monitoring you owe the patient, and how you manage stopping the drug.
This guide lays out the SSRI vs SNRI differences properly: mechanism, named drugs, efficacy evidence, adverse effects, the half-life rule that explains discontinuation symptoms, and a practical framework for choosing an antidepressant. Expect a comparison table, a high-yield exam box, and the four questions trainees ask most.
SSRI vs SNRI: the mechanism difference
SSRIs block the serotonin transporter (SERT) only. By occupying SERT on the presynaptic terminal they prevent serotonin reuptake, increasing 5-HT availability in the synapse. The selectivity is the point: at therapeutic doses SSRIs have negligible affinity for muscarinic, histaminergic and adrenergic receptors, which is why they avoid the sedation, weight gain and postural hypotension of the older tricyclics. Target occupancy of SERT rises steeply with dose and is largely saturated at standard antidepressant doses.
SNRIs block SERT plus the noradrenaline transporter (NET). The added NET blockade recruits noradrenergic tone and is hypothesised to engage descending inhibitory pain pathways — relevant for fatigue, psychomotor retardation and chronic pain. In practice the noradrenergic contribution is dose-dependent: venlafaxine is largely serotonergic at lower doses and gains clinically meaningful NET effects only as the dose climbs.
Named drugs worth knowing. SSRIs: fluoxetine, sertraline, paroxetine, citalopram and escitalopram (fluvoxamine is used mainly for OCD). SNRIs: venlafaxine, duloxetine, desvenlafaxine, milnacipran and levomilnacipran — regional availability varies, so check your local formulary. Duloxetine carries licensed indications for neuropathic pain and chronic musculoskeletal pain, which is why it is the SNRI most often chosen when pain and depression overlap.
If you want structured notes on every receptor interaction, Preppsy's concept library covers the full antidepressant pharmacology set with exam-focused summaries.
Do SNRIs work better than SSRIs?
At class level, no — not meaningfully. Network meta-analyses (Cipriani et al., Lancet 2018, comparing 21 antidepressants) and guideline positions such as NICE depression guidance put SSRIs and SNRIs in a broadly overlapping efficacy band. Individual trials occasionally favour one agent, but head-to-head differences in response rates are small; what differs more between drugs is acceptability — how many patients stay on the drug long enough to benefit.
Two practical corollaries. First, individual variation dominates: a patient who fails an adequate SSRI trial may still respond to an SNRI, and vice versa. Second, expect a lag — antidepressant effects build over 2–4 weeks, sometimes longer. Symptoms like sleep and appetite often improve before mood and cognition. Do not declare failure before two weeks at an adequate dose, and continue the full acute course (NICE advises at least six months of treatment after remission to prevent relapse).
Side-effect profiles: the SSRI vs SNRI trade-off
Both classes share the serotonergic core: nausea and GI upset in the first fortnight, headache, insomnia or drowsiness, and sexual dysfunction — reported in roughly a third to half of patients, and the most common reason for non-adherence. SSRIs additionally carry a bleeding risk (platelet 5-HT uptake is blocked), hyponatraemia/SIADH especially early in older adults, and an initial activation that can worsen anxiety. SNRIs add a dose-dependent rise in blood pressure (most pronounced with venlafaxine), sweating, and dry mouth, on top of the shared serotonergic effects.
| Dimension | SSRI | SNRI |
|---|---|---|
| Mechanism | SERT blockade only | SERT + NET blockade |
| Typical examples | Sertraline, escitalopram, paroxetine, fluoxetine | Venlafaxine, duloxetine, milnacipran |
| Key adverse effects | GI upset, sexual dysfunction, activation, hyponatraemia, bleeding risk | All of the above plus dose-dependent BP rise, sweating, more prominent discontinuation |
| Discontinuation risk | Highest with paroxetine (short half-life) | Highest with venlafaxine (short half-life) |
| Extra monitoring | Sodium in at-risk patients; interactions | Blood pressure during titration |
Discontinuation symptoms are a half-life story
Half-life drives discontinuation risk — not addictiveness. Neither SSRIs nor SNRIs are addictive (no craving, no reward seeking), but abruptly stopping a short-half-life drug drops synaptic transporter occupancy below therapeutic range within days, and the brain's adapted state unwinds as dizziness, "brain zaps", nausea, chills, vivid dreams and irritability — typically starting 1–3 days after the last dose.
Worst offenders: paroxetine (half-life roughly 15–20 hours, plus anticholinergic rebound) and venlafaxine (parent half-life around 5 hours, active metabolite desvenlafaxine around 11 hours). These two account for most discontinuation-syndrome case reports. Fluoxetine is the opposite — parent half-life 2–6 days and norfluoxetine 4–16 days, so it self-tapers over weeks and is classically used to cross-taper patients off a short-half-life SSRI. Duloxetine sits in the middle; missing doses alone can trigger symptoms.
Practical rules: taper rather than stop abruptly, warn patients what to expect, and never let a missed prescription become an unplanned withdrawal. The same serotonin logic explains why combining serotonergic agents risks serotonin syndrome — a favourite exam comparison. Classical MAOI teaching requires a washout (commonly two weeks in either direction, shorter for some agents per local guidance) before starting an SSRI or SNRI.
High-yield
Check blood pressure when titrating an SNRI — the dose-dependent pressor effect is examinable. And when a patient reports withdrawal symptoms after stopping an antidepressant, reach for the half-life: paroxetine and venlafaxine are the classic culprits.
Choosing an antidepressant: a practical framework
- Confirm the diagnosis and severity first. Meet DSM-5-TR or ICD-11 criteria, quantify with a scale such as the PHQ-9, and actively rule out bipolar disorder — an antidepressant unmasked as mania changes everything.
- Default to an SSRI for most patients. Guidelines place an SSRI plus psychological therapy first line; sertraline and escitalopram are common starting points given favourable interaction and QT profiles at usual doses.
- Reach for an SNRI when the picture fits: prominent pain comorbidity (duloxetine), fatigue and psychomotor retardation, or partial response to an SSRI. Switch with a cross-taper rather than stopping cold.
- Check the baggage: CYP2D6 inhibition (fluoxetine, paroxetine) affects codeine and tamoxifen activation; all SSRIs raise bleeding risk with NSAIDs or anticoagulants; citalopram carries QT considerations at higher doses in older adults.
- Review at two weeks, titrate to effect, and plan the exit. Dose increases are guided by response and tolerability, and treatment continues for at least six months after remission for recurrent-risk patients.
Key takeaways
- SSRIs block SERT only; SNRIs block SERT plus NET — one transporter is the entire mechanistic difference.
- Acute efficacy is broadly similar at class level — choice is driven by side effects, comorbidity, interactions and preference.
- SNRIs add a dose-dependent blood pressure rise (venlafaxine especially); SSRIs add bleeding risk, hyponatraemia and activation.
- Discontinuation is a half-life story: paroxetine and venlafaxine are worst; fluoxetine self-tapers.
- Allow 2–4 weeks for onset and continue at least six months after remission to prevent relapse.
The SSRI vs SNRI distinction comes down to one transporter, one blood-pressure check, and one half-life calculation — master those and the exam questions answer themselves. Put the whole antidepressant curriculum to work with Preppsy's AI tutor, which drills mechanism, side effects and guideline sequencing until they are automatic.
Frequently asked questions
What is the difference between SSRIs and SNRIs?
SSRIs inhibit the serotonin transporter (SERT) alone, increasing synaptic serotonin. SNRIs inhibit both SERT and the noradrenaline transporter (NET), adding noradrenergic — and at higher doses, clinically meaningful — effects. The NET component is hypothesised to help pain and low-energy symptoms but also brings a dose-dependent blood-pressure rise.
Which has more side effects, an SSRI or an SNRI?
They share the serotonergic core — GI upset, sexual dysfunction, insomnia or drowsiness, and initial anxiety activation. SSRIs additionally carry bleeding risk, hyponatraemia and drug-interaction burden; SNRIs add dose-dependent hypertension, sweating and dry mouth, plus generally more prominent discontinuation symptoms. Overall burden is similar, but the pattern differs, which is why comorbidity guides choice.
Why do SNRIs cause discontinuation symptoms?
Because of half-life, not addiction. Short-half-life agents like venlafaxine (parent ~5 hours, active metabolite ~11 hours) fall below therapeutic transporter occupancy within days of a missed dose, producing dizziness, brain zaps, nausea and irritability. Paroxetine is the SSRI equivalent. Tapering, and cross-tapering through fluoxetine's long half-life, prevents the syndrome.
Do SNRIs work better than SSRIs for depression?
No convincing class-level advantage exists. Network meta-analyses and NICE guidance place them in a similar efficacy range; what differs more is tolerability for a given patient. An SNRI may be preferred with comorbid neuropathic pain (duloxetine) or after partial SSRI response, but "stronger" is not a valid reason for routine upswitching.
Cover image: “SSRI vs SNRI (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.
